- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04358458
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). All subjects in Part 1 will receive GEN3009, administered at various dose levels in 28-day cycles. Dose Limiting Toxicity (DLT) will be assessed during the first treatment cycle of Part 1 and the Maximum Tolerated Dose (MTD) and/or Recommended phase 2 dose (RP2D) will be identified.
Subjects in Part 2 will be treated with the Part 1-defined RP2D of GEN3009. Some subjects will receive GEN3009 in combination of a fixed dose of another antibody-candidate. Subjects in Part 2 are assigned either to one of 3 groups: Part 2 Monotherapy (hereafter referred to as 'Part 2A'), Part 2 Combination Safety Run-in ('Part2B') or Part 2 Combination ('Part2C').
Various types of B-cell NHLs are studied, including diffuse large B cell lymphoma (DLBCL), high-grade B cell lymphoma (HGBCL), mantle cell lymphoma (MCL), primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Genmab A/S Trial Information
- Phone Number: +4570202728
- Email: clinicaltrials@genmab.com
Study Locations
-
-
-
Antwerp, Belgium
- GZA Ziekenhuizen
-
Charleroi, Belgium
- Grand Hôpital de Charleroi
-
Leuven, Belgium
- UZ Leuven
-
-
-
-
-
Copenhagen, Denmark
- Rigshospitalet
-
Odense, Denmark
- Odense Universitetshospital
-
Vejle, Denmark
- Vejle Sygehus
-
-
-
-
-
Nantes, France
- CHU de Nantes - Hôtel Dieu
-
Nice, France
- Centre Antoine Lacassagne
-
-
-
-
-
Amsterdam, Netherlands
- Amsterdam UMC, Locatie VUMC
-
Groningen, Netherlands
- Universitair Medisch Centrum Groningen (Umcg)
-
Utrecht, Netherlands
- UMC Utrecht
-
-
-
-
-
Barcelona, Spain
- Hospital Clinic de Barcelona
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, Spain
- Hospital Universitario Fundacion Jimenez Diaz
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- ICO Badalona - Hospital Universitari Germans Trias i Pujol
-
-
L'Hospitalet De Llobregat
-
Barcelona, L'Hospitalet De Llobregat, Spain, 08908
- Ico L'Hospitalet - Hospital Duran I Reynals
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- University of Arizona Cancer Center
-
-
California
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Colorado Blood Cancer Institute
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Holden Comprehensive Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Oregon
-
Portland, Oregon, United States, 97210
- OHSU Knight Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania School of Medicine
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina (MUSC)
-
-
Texas
-
Dallas, Texas, United States, 75390
- The University of Texas Southwestern Medical Center
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98133
- University of Washington - Seattle Cancer Care Alliance
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Be at least 18 years of age.
- Must sign an informed consent form prior to any screening procedures.
Dose Escalation: Has histologically or cytologically confirmed relapsed and/or refractory B-cell NHL with no available standard therapy or is not a candidate for available standard therapy, and for whom, in the opinion of the investigator, the experimental therapy may be beneficial. All subjects must have received at least two prior lines of systemic therapy.
Dose Expansion: Has histologically or cytologically confirmed relapsed or refractory B-cell NHL. All subjects must have received at least 2 prior lines of systemic therapy, and,
- For FL and DLBCL, at least 1 of the 2 prior lines of treatment must have been a CD20 containing systemic regimen;
- For CLL, subjects must have received at least one prior line of BTK inhibitor or BCL 2 inhibitor.
Has one of the eligible subtypes of B-cell NHL :
Dose Escalation: (DLBCL, HGBCL, PMBCL, FL, MCL, MZL, SLL, or CLL). Dose Expansion: (DLBCL, FL, CLL)
- Has measurable disease for B-cell NHL or has active disease for Chronic Lymphocytic Leukemia (CLL).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Has adequate hepatic, renal, and bone marrow functions.
- Before the first dose of GEN3009, during the trial, and for 12 months after the last dose of GEN3009 and/or the combination, a woman must be either not of childbearing potential or of childbearing potential and practicing a highly effective method of birth control, and must have a negative serum beta-human chorionic gonadotropin (beta-hCG) and urine pregnancy test at screening.
- A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control.
- Subjects must have a life expectancy of at least 3 months.
Key Exclusion Criteria:
- Prior treatment with a CD37-targeting agent.
- Prior allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
- Prior treatment with a CD3xCD20 bispecific antibody (Combination Expansion cohort only).
- Autologous HSCT within 3 months before the first dose of GEN3009.
- Lymphomas leukemic phase: high absolute lymphocyte count or the presence of abnormal cells in the peripheral blood indicating circulating lymphoma cells.
- Treatment with an anti-cancer biologic including anti-CD20 therapy, radio-conjugated or toxin-conjugated antibody or chimeric antigen receptor (CAR) T-cell therapy within 4 weeks or 5 half-lives, whichever is shorter, before the first dose of GEN3009. Treatment with small molecules such as BTK inhibitors, BCL2 inhibitors, or PI3K inhibitors within 5 half-lives prior to the first dose of GEN3009.
- Chemotherapy or radiation therapy within 2 weeks of the first dose of GEN3009.
- Treatment with an investigational drug or an invasive investigational medical device within 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of GEN3009, and at any time during the study treatment period.
- Autoimmune disease or other diseases that require permanent or high-dose immunosuppressive therapy.
- Received a cumulative dose of corticosteroids more than the equivalent of 250 mg of prednisone within the 2-week period before the first dose of GEN3009.
- Has uncontrolled intercurrent illness.
- Seizure disorder requiring therapy (such as steroids or anti-epileptics) (Combination Expansion cohort only).
- Toxicities from previous anti-cancer therapies have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.
- Primary central nervous system (CNS) lymphoma or known CNS involvement at screening.
- Known past or current malignancy other than inclusion diagnosis.
- Had allergic reactions to anti-CD20 or anti-CD37 monoclonal antibody treatment or intolerant to GEN3009 or to the combination therapy excipients.
- Has had major surgery within 4 weeks before screening or will not have fully recovered from surgery, or has major surgery planned during the time the subject is expected to participate in the trial (or within 4 weeks after the last dose of GEN3009 and/or the combination therapy).
- Known history/positive serology for hepatitis B.
- Known medical history or ongoing hepatitis C infection that has not been cured.
- Known history of seropositivity for HIV infection.
- Is a woman who is pregnant or breast-feeding, or who is planning to become pregnant while enrolled in this trial or within 12 months after the last dose of GEN3009 and/or the combination therapy.
- Is a man who plans to father a child while enrolled in this trial or within 12 months after the last dose of GEN3009 and/or the combination therapy.
- Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments. Additionally, vulnerable subjects or subjects under guardianship, curatorship, judicial protection or deprived of liberty), are excluded from participation in this trial.
- Exposed to live/live attenuated vaccine within 4 weeks prior to initiation of GEN3009 treatment.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Monotherapy Arm
|
GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
Other Names:
|
Experimental: Combination Arm
|
GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
Other Names:
Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 and Part 2B: Dose liming toxicity (DLT)
Time Frame: During the first treatment cycle (28 days) in each cohort
|
To identify the recommended phase 2 dose (RP2D) and if reached, the MTD
|
During the first treatment cycle (28 days) in each cohort
|
Part 1 and Part 2B: Incidence of Adverse Events
Time Frame: From screening until 30 days after last dose for Part 1 and 60 days after last dose for Part 2B
|
To assess the safety and tolerability of GEN3009 as monotherapy and of GEN3009 in combination
|
From screening until 30 days after last dose for Part 1 and 60 days after last dose for Part 2B
|
Part 1 and Part 2B: Number of participants with clinically significant shifts from baseline in clinical laboratory parameters
Time Frame: From screening until 30 days after last dose for Part 1 and 60 days after last dose for Part 2B
|
Clinical laboratory parameters assessed: hematology, chemistry, coagulation, immunoglobulins and urinalyses
|
From screening until 30 days after last dose for Part 1 and 60 days after last dose for Part 2B
|
Part 1 and Part 2B: Number of participants with clinically significant shifts from baseline in vital signs
Time Frame: From screening until 30 days after last dose for Part 1 and 60 days after last dose for Part 2B
|
Vital signs assessed: systolic and diastolic blood pressure, heart rate, temperature and pulse oximetry
|
From screening until 30 days after last dose for Part 1 and 60 days after last dose for Part 2B
|
Part 1 and Part 2B: Number of participants with dose interruptions and dose delays, including dose intensity
Time Frame: From enrollment until treatment discontinuation (assessed up to 5 years)
|
Assessment of frequency of dose interruptions, dose delays and dose intensity
|
From enrollment until treatment discontinuation (assessed up to 5 years)
|
Part 2A: Objective Response Rate (ORR)
Time Frame: From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
To evaluate preliminary anti-tumor efficacy of GEN3009 as monotherapy by change in tumor size
|
From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
Part 2C: Complete Response (CR) rate
Time Frame: From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
To evaluate preliminary anti-tumor efficacy of GEN3009 in combination by change in tumor size
|
From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total body clearance of drug from the plasma (CL)
Time Frame: At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
|
Volume of Distribution
Time Frame: At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
|
Area Under the Concentration-Time Curve (AUC) from Time 0 to Day 7
Time Frame: At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
|
The AUC from Time 0 to Infinity (AUCinf)
Time Frame: At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
|
The AUC from Time 0 to time of last dose (AUClast)
Time Frame: At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
|
Maximum observed concentration (Cmax)
Time Frame: At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
|
Time to reach Cmax (Tmax)
Time Frame: At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
|
Trough concentrations (Ctrough)
Time Frame: At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
|
Terminal Elimination Half-Life (t 1/2)
Time Frame: At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
At enrollment and at multiple timepoints until treatment discontinuation (assessed up to 5 years)
|
|
Incidence of anti-drug antibodies [ADAs]
Time Frame: From enrollment until treatment discontinuation (assessed up to 5 years)
|
From enrollment until treatment discontinuation (assessed up to 5 years)
|
|
Duration of Response (DoR)
Time Frame: From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
To evaluate preliminary anti-tumor efficacy of GEN3009 as monotherapy and in combination by change in tumor size
|
From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
Time to Response (TTR)
Time Frame: From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
To evaluate preliminary anti-tumor efficacy of GEN3009 as monotherapy and in combination by change in tumor size
|
From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
Progression-free survival (PFS)
Time Frame: From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
To evaluate preliminary anti-tumor efficacy of GEN3009 as monotherapy and in combination by change in tumor size
|
From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
Overall survival (OS)
Time Frame: From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
To evaluate preliminary anti-tumor efficacy of GEN3009 as monotherapy and in combination by change in tumor size
|
From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
Part 2C: Rate and Duration of MRD negativity
Time Frame: From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
To evaluate preliminary anti-tumor efficacy of GEN3009 in combination by change in tumor size
|
From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
Part 1, Part 2B and part 2C: Objective Response Rate (ORR)
Time Frame: From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
To evaluate preliminary anti-tumor efficacy of GEN3009 as monotherapy and in combination by change in tumor size
|
From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
Part 1, Part 2A and Part 2B: Complete Response (CR) rate
Time Frame: From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
To evaluate preliminary anti-tumor efficacy of GEN3009 as monotherapy and in combination by change in tumor size
|
From 6 weeks after enrollment until treatment discontinuation, assessed up to 5 years
|
Part 2A and 2C: Incidence of Adverse Events
Time Frame: From screening until 30 days after last dose for Part 2A and 60 days after last dose for Part 2C
|
To assess the safety and tolerability of GEN3009 as monotherapy and of GEN3009 in combination
|
From screening until 30 days after last dose for Part 2A and 60 days after last dose for Part 2C
|
Part 2A and 2C: Number of participants with clinically significant shifts from baseline in clinical laboratory
Time Frame: From screening until 30 days after last dose for Part 2A and 60 days after last dose for Part 2C
|
Clinical Lab parameters assessed: hematology, chemistry, coagulation, immunoglobulins and urinalyses
|
From screening until 30 days after last dose for Part 2A and 60 days after last dose for Part 2C
|
Part 2A and 2C: Number of participants with clinically significant change from baseline in vital signs
Time Frame: From screening until 30 days after last dose for Part 2A and 60 days after last dose for Part 2C
|
Vital signs assessed: systolic and diastolic blood pressure, heart rate, temperature and pulse oximetry
|
From screening until 30 days after last dose for Part 2A and 60 days after last dose for Part 2C
|
Part 2A and 2C: Frequency of dose interruptions, dose delays, and dose intensity
Time Frame: From enrollment until treatment discontinuation (assessed up to 5 years)
|
Assessment of frequency of dose interruptions, dose delays and dose intensity
|
From enrollment until treatment discontinuation (assessed up to 5 years)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Disease Attributes
- Leukemia, Lymphoid
- Leukemia
- Leukemia, B-Cell
- Chronic Disease
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
Other Study ID Numbers
- GCT3009-01
- 2019-002752-16 (EudraCT Number)
- NL72025.056.20 (Registry Identifier: The Netherlands CCMO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States